Regulation of angiogenesis and endothelial cell motility by matrix-bound fibroblasts

Angiogenesis

Volumn 3, Issue 1, 1999, Pages 69-76

  Martin, T A ^a   Harding, K G ^a   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Angiogenesis; Endothelial cell motility; HGF SF; Matrix bound fibroblasts; VEGf

Indexed keywords

EID: 0003098442     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009004212357     Document Type: Article

References (31)

1. Sheu JR, Yen M-H, Kan Y-C et al. Inhibition of angiogenesis in vitro and in vivo: Comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-αVβ3 integrin monoclonal antibody. Biochim Biophys Acta 1997; 1336: 445-54.
2. Grant DS, Kleinmann HK, Goldberg ID et al. Scatter factor induces blood vessel formation in vitro. Proc Natl Acad Sci USA 1993; 90: 1937-41.
3. Jiang WG, Harding KG. Enhancement of wound tissue expansion and angiogenesis by matrix-embedded fibroblast (Matrix-bound fibroblasts), a role of hepatocyte growth factor/scatter factor. Int J Mol Med 1998; 2: 203-10.
4. Clark RAF. Regulation of fibroplasia in cutaneous wound repair. Am J Med Sci 1993; 306(1): 42-8.
5. Grinnell F. Fibroblasts, myofibroblasts and wound contraction. J Cell Biol 1994; 124(4): 401-4.
6. Gailit J, Clark RAF. Studies in vitro on the role of αV and β1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vitronectin, and fibrinogen. J Invest Dermatol 1996; 106(1): 102-8.
7. Jiang WG, Hiscox S. Hepatocyte growth factor/scatter facor, a cytokine playing multiple and converse roles. Histol Histopathol 1997; 12: 537-55.
8. Maggiora P, Gambarotta G, Olivera M et al. Control of invasive growth by the HGF receptor family. J Cell Physiol 1997; 173: 183-86.
9. Van Belle E, Witzenbichler B, Chen D et al. Potential angiogenic effect of scatter factor/HGF via induction of vascular endothelial growth factor - the case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-90.
10. Miyazaki M, Gohda E, Kaji K, Namba M. Increased hepatocyte growth factor production by aging human fibroblasts mainly due to autocrine stimulation by interleukin-1. Biochem Biophys Res Comm 1998; 246: 255-60.
11. Salven P, Lymboussak A, Heikkila P et al. Vascular endothelial growth factors VEGf-B and VEGf-C are expressed in human tumours. Am J Pathol 1998; 153(1): 103-8.
12. Aggarwal BB, Puri RK (eds). Human Cytokines: Their Role in Disease Therapy. USA: Blackwell Science 1995.
13. Rosenstein JM, Mani N, Silverman WF, Krum JM. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 7086-91.
14. Roeckl W, Hecht D, Sztajer H et al. Differential binding characteristics and cellular inhibition by soluble VEGf receptors 1 and 2. Exp Cell Res 1998; 241: 161-70.
15. Pepper MS, Mandriota SJ. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cell. Exp Cell Res 1998; 241: 414-25.
16. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatmant of diabetic foot ulcers. Artificial Organs 1997; 21(11): 1203-10.
17. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of matrix-bound fibroblasts, a cultured human dermis, to heat diabetic foot ulcers. Diabetes Care 1996 19(4): 350-4.
18. Landeen LK, Ziegler FC, Halberstadt C. Characterisation of a human dermal replacement. Wounds 1992; 5: 167-75.
19. Jiang WG, Hiscox S, Horobin DF et al. Expression of cadherin in human cancer cells and its regulation by n-6 polyunsaturated fatty acids. Anticancer 1995; 15: 2569-74.
20. Rosen E, Meromsky L, Setter E et al. Smooth muscle-derived factor stimulates mobility of human tumour cells. Invasion Metastasis 1990; 10: 49-64.
21. Albrecht-Buehler G. The phagokinetic tracks of 3T3 cells. Cell 1977; 11: 395-404.
22. Nicosia RF, Ottinetti A. Growth of mivrovessels in serum-free matrix culture of rat aorta. Lab Invest 1990; 63(1): 115-22.
23. Schaffer CJ, Nanney LB. Cell biology of wound healing. Int Rev Cytol 1996; 169: 151-81.
24. Bussolino F, DiRenzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which simulates endothelial cell motility and growth. J Cell Biol 1992; 119(3): 629-41.
25. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267(267): 10931-4.
26. Arthur W, Vernon RB, Sage EH, Reed MJ. Growth factors reverse the impaired sprouting of micro-vessels from aged mice. Microvasc Res 1998; 55: 260-70.
27. Strombold S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6: 462-8.
28. Hino M, Inaba M, Goto H et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 1996; 73: 119-23.
29. Nakamura T, Nishizawa T, Hagiya M et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3.
30. Jiang WG, Puntis MCA, Hallett MB. Monocyte conditioned media posess a novel factor which increases motility of cancer cells. Int J Cancer 1993; 53: 426-31.
31. Jiang WG, Bryce RP, Mansel RE. Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells. Prostaglandins, Leukotrienes and Essential Fatty Acids 1997; 56: 307-16.